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Mortality and pulmonary complications in patients 
undergoing surgery with perioperative SARS-CoV-2 
infection: an international cohort study
COVIDSurg Collaborative*
Summary
Background The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery 
needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study 
reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection.
Methods This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing 
surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome 
measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome 
measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected 
postoperative ventilation.
Findings This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) 
had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 
294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 
1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all 
deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], 
p<0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p<0·0001), American Society of 
Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p<0·0001), malignant versus benign or obstetric 
diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major 
versus minor surgery (1·52 [1·01–2·31], p=0·047).
Interpretation Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 
infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be 
higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given 
for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for 
surgery.
Funding National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, 
Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, 
British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, 
NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) has now spread to most countries, with 
WHO declaring a COVID-19 pandemic on March 11, 2020.1 
The pandemic has tested the resilience of health-care 
systems, including hospitals, which were largely unpre-
pared for the scale of the pandemic.2 Patients having 
surgery are a vulnerable group at risk of SARS-CoV-2 
exposure in hospital and might be particularly susceptible 
to subsequent pulmonary complications, due to the 
pro-inflammatory cytokine and immunosuppressive res-
ponses to surgery and mechanical ventilation.3,4 Evidence 
of the safety of performing surgery in SARS-CoV-2-
exposed hospitals is urgently needed.
Before the SARS-CoV-2 pandemic, high-quality, 
multinational observational studies established overall 
baseline rates of postoperative pulmonary complications 
(up to 10%) and subsequent mortality (up to 3%) after 
surgery.5–7 With initiatives such as the UK’s National 
Emergency Laparotomy Audit (NELA), mortality was 
improving even in high-risk groups.8
Guidelines have been published for the management of 
surgical patients during the SARS-CoV-2 pandemic,9–11 
but they are based solely on expert opinion. The impact of 
SARS-CoV-2 on postoperative pulmonary complications 
and mortality needs to be established in order to enable 
surgeons and patients to make evidence-based decisions 
during the pandemic. This study reports the clinical 
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outcomes of patients who had surgery with perioperative 
SARS-CoV-2 infection, including the impact of pulmonary 
complications.
Methods
Study design
We did an international, multicentre, observational cohort 
study in patients with SARS-CoV-2 infection who had 
surgery at 235 hospitals in 24 countries (appendix p 10). 
Data release and ethical considerations were discussed 
with an independent data monitoring and ethics 
committee. We collected only routine, anonymised data 
with no change to clinical care pathways. In the UK, the 
study was registered at each site as either a clinical audit 
or service evaluation; at the lead centre (University 
Hospital Birmingham) it was approved as clinical audit, 
with registration CARMS-15986. In other countries, local 
principal investigators were responsible for contacting 
competent research ethics committees to obtain local or 
national approvals in line with applicable regulations, as 
well as seeking approvals from data protection officers. In 
some participating hospitals, informed patient consent 
was taken, whereas in other countries the requirement 
for patient consent was waived by local research ethics 
committees.
Participants
Each participating hospital included all patients 
undergoing surgery who had SARS-CoV-2 infection 
diagnosed within 7 days before or 30 days after surgery. 
Surgery was defined as any procedure done by a sur-
geon in an operating theatre under general, regional, or 
local anaesthesia. Patients undergoing surgery for any 
indication were eligible, including benign disease, cancer, 
trauma, and obstetrics. The study included children 
and adults, but individual hospitals had the option to 
apply local age cutoffs, if appropriate. If patients with 
SARS-CoV-2 infection had multiple operations, the proce-
dure closest to the time of confirmation of SARS-CoV-2 
infection was defined as the index procedure.
Participating hospitals prospectively screened patients 
for eligibility to ensure that all patients fulfilling eligibility 
criteria were captured. However, the study was initiated 
after the SARS-CoV-2 pandemic had peaked in some 
regions, so retrospective data collection was permitted if 
collaborators were able to identify and include all eligible 
patients. The importance of working across surgical 
specialties to identify all eligible patients was highlighted 
in site training, because incomplete case ascertainment 
could introduce bias, if patients with less severe disease 
were missed. Site inves tigators were provided with a 
range of written materials setting out possible strategies 
to capture consecutive eligible patients. In addition, 
investigators were invited to join social media groups 
and teleconferences for the purpose of troubleshooting 
site-specific recruitment issues and shared learning.
Procedures
Laboratory testing for SARS-CoV-2 infection was based 
on viral RNA detection by quantitative RT-PCR. Sampling, 
including nasal swabs or bronchoalveolar lavage, and 
analyses were done according to individual hospital 
protocols.
As quantitative RT-PCR testing was not available at 
all participating hospitals, patients were also included 
based on either clinical or radiological findings. Clinical 
Research in context
Evidence before this study
We searched PubMed and Embase on March 15, 2020, 
for studies reporting on surgical patients during the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic. We used the search terms "COVID-19", 
"SARS-CoV-2", "coronavirus", and "pandemic", in combination 
with "surgery", and applied no language or date restrictions. 
We identified 13 articles (12 from China and one from 
Singapore), all of which provided clinical guidance, with none 
reporting patient-level outcomes.
Added value of this study
This international, observational, cohort study provides cross-
specialty, patient-level outcomes data for patients who had 
surgery and acquired perioperative SARS-CoV-2 infection. 
1128 patients were included across 24 countries. Overall 30-day 
mortality was 23·8% (268 of 1128 patients). Pulmonary 
complications occurred in 577 (51·2%) patients; these patients 
accounted for 82·6% (219 of 265) of all deaths. Independent 
risk factors for mortality were male sex, age 70 years or older, 
American Society of Anesthesiologists grades 3–5, surgery for 
malignant disease, emergency surgery, and major surgery.
Implications of all the available evidence
Postoperative pulmonary complications occur in half of 
patients with perioperative SARS-CoV-2 infection and are 
associated with high mortality. These pulmonary complication 
and mortality rates are greater than those reported for even the 
highest-risk patients before the pandemic. Thresholds for 
surgery during the SARS-CoV-2 pandemic should be higher 
than during normal practice; men aged 70 years and older who 
have emergency or major elective surgery are at particularly 
high risk of mortality. Consideration should be given for 
postponing non-critical procedures and promoting 
non-operative treatment to delay or avoid the need for surgery. 
When hospitals recommence routine surgery, this will be in 
hospital environments that remain exposed to SARS-CoV-2, 
so strategies should be developed to reduce in-hospital 
SARS-CoV-2 transmission and mitigate the risk of 
postoperative complications.
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30-day mortality Pulmonary complications
No (n=845) Yes (n=268) p value No (n=526) Yes (n=577) p value
Age ·· ·· <0·0001 ·· ·· 0·00023
<29 years 56 (100%) 0 ·· 39 (70·9%) 16 (29·1%) ··
30–49 years 146 (94·2%) 9 (5·8%) ·· 86 (55·8%) 68 (44·2%) ··
50–69 years 277 (79·8%) 70 (20·2%) ·· 159 (46·0%) 187 (54·0%) ··
≥70 years 364 (65·9%) 188 (34·1%) ·· 240 (44·0%) 305 (56·0%) ··
Missing 2 1 ·· 2 1 ··
Sex ·· ·· <0·0001 ·· ·· 0·0028
Male 424 (71·1%) 172 (28·9%) ·· 252 (42·8%) 337 (57·2%) ··
Female 417 (81·6%) 94 (18·4%) ·· 270 (53·1%) 238 (46·9%) ··
Ambiguous 1 (50·0%) 1 (50·0%) ·· 1 (50·0%) 1 (50·0%) ··
Missing 3 1 ·· 3 1 ··
American Society of 
Anesthesiologists grade
·· ·· <0·0001 ·· ·· <0·0001
1–2 344 (88·4%) 45 (11·6%) ·· 235 (60·6%) 153 (39·4%) ··
3–5 475 (68·7%) 216 (31·3%) ·· 278 (40·6%) 407 (59·4%) ··
Missing 26 7 ·· 13 17 ··
Number of comorbidities ·· ·· <0·0001 ·· ·· 0·00017
None 107 (93·0%) 8 (7·0%) ·· 73 (63·5%) 42 (36·5%) ··
One 192 (82·8%) 40 (17·2%) ·· 115 (50·7%) 112 (49·3%) ··
Two or more 527 (70·8%) 217 (29·2%) ·· 322 (43·5%) 418 (56·5%) ··
Missing 19 3 ·· 16 5 ··
Comorbidities
Current smoker 80 (75·5%) 26 (24·5%) 0·909 42 (40·0%) 63 (60·0%) 0·097
Asthma 57 (73·1%) 21 (26·9%) 0·542 36 (48·0%) 39 (52·0%) 0·955
Cancer 146 (77·2%) 43 (22·8%) 0·639 92 (48·9%) 96 (51·1%) 0·707
Chronic kidney disease 109 (66·5%) 55 (33·5%) 0·0022 64 (39·3%) 99 (60·7%) 0·020
Chronic obstructive pulmonary 
disease
75 (64·7%) 41 (35·3%) 0·0027 44 (37·9%) 72 (62·1%) 0·026
Congestive heart failure 55 (64·7%) 30 (35·3%) 0·012 29 (34·5%) 55 (65·5%) 0·012
Dementia 48 (55·2%) 39 (44·8%) <0·0001 30 (35·3%) 55 (64·7%) 0·017
Diabetes 207 (73·9%) 73 (26·1%) 0·367 124 (44·1%) 157 (55·9%) 0·166
Hypertension 399 (71·0%) 163 (29·0%) 0·00010 253 (45·3%) 305 (54·7%) 0·114
Myocardial infarction 70 (63·1%) 41 (36·9%) 0·00084 39 (35·4%) 71 (64·6%) 0·0068
Peripheral vascular disease 67 (62·0%) 41 (38·0%) 0·00038 48 (44·4%) 60 (55·6%) 0·477
Stoke or transient ischaemic attack 55 (61·1%) 35 (38·9%) 0·00061 45 (50·0%) 45 (50·0%) 0·647
Symptoms at admission*
No symptoms reported 111 (77·6%) 32 (22·4%) 0·281 78 (56·5%) 60 (43·5%) 0·020
Symptoms reported 499 (73·3%) 182 (26·7%) ·· 309 (45·6%) 368 (54·4%) ··
Abdominal pain 193 (77·5%) 56 (22·5%) 0·134 122 (49·4%) 125 (50·6%) 0·472
Dyspnoea 83 (61·9%) 51 (38·1%) 0·00049 32 (23·9%) 102 (76·1%) <0·0001
Cough 108 (73·0%) 40 (27·0%) 0·746 55 (37·2%) 93 (62·8%) 0·0054
Diarrhoea 18 (69·2%) 8 (30·8%) 0·571 12 (46·2%) 14 (53·8%) 0·890
Fatigue 42 (70·0%) 18 (30·0%) 0·460 18 (30·0%) 42 (70·0%) 0·0048
Fever >38°C 177 (76·6%) 54 (23·4%) 0·289 94 (40·9%) 136 (59·1%) 0·018
Haemoptysis 2 (66·7%) 1 (33·3%) 0·771 1 (33·3%) 2 (66·7%) 0·623
Myalgia 27 (79·4%) 7 (20·6%) 0·465 9 (26·5%) 25 (73·5%) 0·012
Nausea or vomiting 100 (79·4%) 26 (20·6%) 0·138 62 (49·6%) 63 (50·4%) 0·607
Sputum 7 (41·2%) 10 (58·8%) 0·0018 6 (35·3%) 11 (64·7%) 0·309
Other 209 (70·6%) 87 (29·4%) 0·094 139 (47·3%) 155 (52·7%) 0·930
(Table 1 continues on next page)
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30-day mortality Pulmonary complications
No (n=845) Yes (n=268) p value No (n=526) Yes (n=577) p value
(Continued from previous page)
Preoperative respiratory support
None or oxygen only 805 (76·4%) 249 (23·6%) 0·134 520 (49·7%) 526 (50·3%) <0·0001
Non-invasive ventilation 12 (80·0%) 3 (20·0%) 0·710 1 (6·7%) 14 (93·3%) 0·0014
Invasive ventilation 31 (66·0%) 16 (34·0%) 0·103 2 (4·3%) 45 (95·7%) <0·0001
Last available values before surgery
Systolic blood pressure, mm Hg† 129·0 (22·6) 131·7 (26·0) 0·118 129·9 (22·0) 129·7 (24·6) 0·896
Respiratory rate, rpm† 18·1 (5·5) 18·7 (8·8) 0·211 17·5 (5·6) 18·9 (7·1) 0·0013
Heart rate, bpm† 85·0 (18·3) 83·0 (19·0) 0·130 83·4 (16·9) 85·3 (19·6) 0·081
qSOFA score ·· ·· 0·011 ·· ·· <0·0001
0 572 (76·3%) 178 (23·7%) ·· 382 (51·3%) 362 (48·7%) ··
1 155 (77·5%) 45 (22·5%) ·· 73 (36·7%) 126 (63·3%) ··
≥2 37 (59·7%) 25 (40·3%) ·· 9 (14·8%) 52 (82·2%) ··
Missing 81 20 ·· 62 37 ··
Data only presented for patients with 30-day mortality outcome available (n=1113%) and pulmonary complications outcome available (n=1103%). Percentages are presented 
in rows. bpm=beats per min. qSOFA=quick sequential organ failure assessment. rpm=breaths per min. *Data only presented for emergency patients. †Data presented as mean 
with SD.
Table 1: Baseline and demographic characteristics
30-day mortality Pulmonary complications
No (n=845) Yes (n=268) p value No (n=526) Yes (n=577) p value
Haemoglobin, g/L* 118·6 (24·7) 116·1 (24·1) 0·150 118·5 (23·5) 117·6 (25·4) 0·537
Missing 18 4 ·· 15 7 ··
White blood cell count, ×10⁹ per L* 10·5 (7·6) 10·6 (6·8) 0·859 10·1 (5·1) 10·8 (8·9) 0·169
Missing 19 4 ·· 15 8 ··
Preoperative chest x-ray ·· ·· 0·0041 ·· ·· <0·0001
Not performed 320 (79·4%) 83 (20·6%) ·· 232 (58·0%) 168 (42·0%) ··
Yes: normal 321 (77·4%) 94 (22·6%) ·· 205 (49·8%) 207 (50·2%) ··
Yes: abnormal 199 (68·9%) 90 (31·1%) ·· 84 (29·4%) 202 (70·6%) ··
Missing 5 1 ·· 5 0 ··
Preoperative thorax CT
Not performed 598 (78·1%) 168 (21·9%) 0·013 376 (49·5%) 384 (50·5%) 0·077
Performed: normal 96 (75·0%) 32 (25·0%) 0·796 60 (47·6%) 66 (52·4%) 0·987
Performed: consolidation 44 (75·9%) 14 (24·14%) 0·991 23 (39·7%) 35 (60·3%) 0·208
Performed: ground glass opacity 57 (71·3%) 23 (28·7%) 0·310 31 (39·2%) 48 (60·8%) 0·119
Performed: pulmonary 
infiltration
27 (67·5%) 13 (32·5%) 0·205 13 (33·3%) 26 (66·7%) 0·068
Performed: other abnormality 50 (61·0%) 32 (39·0%) 0·0010 30 (37·0%) 51 (63·0%) 0·046
SARS-CoV-2 diagnosis ·· ·· 0·719 ·· ·· 0·085
Laboratory confirmed 727 (76·0%) 230 (24·0%) ·· 454 (47·9%) 493 (52·1%) ··
Radiological (CT thorax) 58 (72·5%) 22 (27·5%) ·· 29 (36·3%) 51 (63·7%) ··
Clinical 53 (77·9%) 15 (22·1%) ·· 36 (52·9%) 32 (47·1%) ··
Missing 7 1 ·· 7 1 ··
Timing of SARS-CoV-2 diagnosis ·· ·· 0·128 ·· ·· 0·155
Preoperative 231 (78·8%) 62 (21·2%) ·· 148 (51·0%) 142 (49·0%) ··
Postoperative 595 (74·4%) 205 (25·6%) ·· 367 (46·2%) 428 (53·8%) ··
Missing 19 1 ·· 11 7 ··
Data only presented for patients with 30-day mortality outcome available (n=1113) and pulmonary complications outcome available (n=1103). Percentages are presented 
in rows.  SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. *Last available blood test results from before surgery, presented as mean with SD.
Table 2: Preoperative assessment
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diagnosis consistent with SARS-CoV-2 infection was 
made by a senior physician and based on clinical presen-
tation of symptoms highly indicative of SARS-CoV-2 
infec tion, including cough, fever, and myalgia.12 Radio-
logical diagnosis was based on thorax CT, in keeping 
with locally implemented protocols. All patients included 
initially based on clinical or radiological criteria who 
subsequently had laboratory testing for SARS-CoV-2 
infection and returned a negative result were excluded 
from the study.
Data were collected online using the Research 
Electronic Data Capture web application. Demographic 
variables recorded included age, sex, and American 
Society of Anesthesiologists (ASA) physical status 
classification. Age was collected as a categorical variable 
by deciles of age. ASA at the time of surgery was ana-
lysed as grades 1–2 versus grades 3–5. The timing 
of SARS-CoV-2 diagnosis was recorded as either 
preoperative or postoperative. Clinical symptoms present 
at the time of hospital admission were recorded for 
emergency admissions. Physiological variables recorded 
(respiratory rate, heart rate, and blood pressure) were 
based on readings taken immediately before surgery. The 
quick sequential organ failure assessment score13 was 
calculated on the basis of individual variables recorded 
immediately before surgery. Operative variables included 
urgency (elective or emergency surgery), primary 
procedure completed, and anaesthesia used (local, 
30-day mortality Pulmonary complications
No (n=845) Yes (n=268) p value No (n=526) Yes (n=577) p value
Urgency of surgery ·· ·· 0·020 ·· ·· 0·873
Elective 225 (80·9%) 53 (19·1%) ·· 130 (46·9%) 147 (53·1%) ··
Emergency 610 (74·0%) 214 (26·0%) ·· 387 (47·5%) 428 (52·5%) ··
Missing 10 1 ·· 9 2 ··
Anaesthesia ·· ·· 0·383 ·· ·· 0·488
Local 34 (69·4%) 15 (30·6%) ·· 24 (49·0%) 25 (51·0%) ··
Regional 119 (78·8%) 32 (21·2%) ·· 78 (51·7%) 73 (48·3%) ··
General 658 (75·2%) 217 (24·8%) ·· 403 (46·5%) 464 (53·5%) ··
Missing 34 4 ·· 21 15 ··
Surgical diagnosis ·· ·· 0·030 ·· ·· 0·502
Benign or obstetric case 480 (78·3%) 133 (21·7%) ·· 281 (46·3%) 326 (53·7%) ··
Cancer 183 (72·9%) 68 (27·1%) ·· 114 (45·6%) 136 (54·4%) ··
Trauma 157 (70·1%) 67 (29·9%) ·· 112 (50·5%) 110 (49·6%) ··
Missing 25 0 ·· 19 5 ··
Grade of surgery ·· ·· 0·00055 ·· ·· 0·022
Minor 209 (83·6%) 41 (16·4%) ·· 132 (53·2%) 116 (46·8%) ··
Major 607 (72·9%) 226 (27·1%) ·· 372 (45·0%) 455 (55·0%) ··
Missing 29 1 ·· 22 6 ··
Specialty ·· ·· <0·0001 ·· ·· <0·0001
Breast 3 (100·0%) 0 (0%) ·· 2 (66·6%) 1 (33·3%) ··
Cardiac 33 (66·0%) 17 (34·0%) ·· 3 (5·9%) 48 (94·1%) ··
Gastrointestinal and general 286 (76·9%) 86 (23·1%) ·· 172 (46·4%) 199 (53·6%) ··
Gynaecology 20 (95·2%) 1 (4·8%) ·· 16 (76·2%) 5 (23·8%) ··
Head and neck 32 (80·0%) 8 (20·0%) ·· 10 (25·6%) 29 (74·4%) ··
Hepatobiliary 50 (84·8%) 9 (15·2%) ·· 29 (50·9%) 28 (49·1%) ··
Neurosurgery 31 (81·6%) 7 (18·4%) ·· 19 (50·0%) 19 (50·0%) ··
Obstetrics 50 (98·0%) 1 (2·0%) ·· 26 (51·0%) 25 (49·0%) ··
Ophthalmology 4 (100·0%) 0 (0%) ·· 3 (75·0%) 1 (25·0%) ··
Orthopaedics 213 (71·2%) 86 (28·8%) ·· 165 (55·7%) 131 (44·3%) ··
Other 19 (73·1%) 7 (26·9%) ·· 11 (42·3%) 15 (57·7%) ··
Plastic and reconstructive 3 (100·0%) 0 (0%) ·· 1 (33·3%) 2 (66·7%) ··
Thoracic 20 (57·1%) 15 (42·9%) ·· 12 (34·3%) 23 (65·7%) ··
Urology 25 (67·6%) 12 (32·4%) ·· 15 (42·3%) 20 (57·1%) ··
Vascular 27 (60·0%) 18 (40·0%) ·· 20 (44·4%) 25 (55·6%) ··
Missing 29 (96·7%) 1 (3·3%) ·· 22 (78·6%) 6 (21·4%) ··
Data only presented for patients with 30-day mortality outcome available (n=1113) and pulmonary complications outcome available (n=1103). Percentages are presented in rows.
Table 3: Operative details
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regional, or general). Emergency surgery was defined 
as procedures classified by the National Confidential 
Enquiry into Patient Outcome and Death as immediate, 
urgent, or expedited.14 Grade of surgery was categorised 
on the basis of the Bupa schedule of procedures as either 
minor (minor or intermediate according to the Bupa 
schedule) or major (major or complex major according to 
the Bupa schedule). Before locking of the dataset for 
analysis, the senior local principal investigator for each 
hospital was asked to confirm data completeness and 
that all eligible patients had been entered into the 
database.
Outcomes
The primary outcome was 30-day mortality, with the day 
of surgery defined as day 0. The key secondary outcome 
measure was the rate of pulmonary complications, a 
composite outcome adapted from the Prevention of 
Respiratory Insufficiency after Surgical Management 
trial.15,16 Pulmonary complications were defined as pneu-
monia, acute respiratory distress syndrome (ARDS), or 
unexpected postoperative ventilation; these are the most 
frequent COVID-19-related pulmonary complications in 
medical patients.12 Unexpected postoperative ventilation 
was defined as either any episode of non-invasive venti-
lation, invasive ventilation, or extracorporeal membrane 
oxygenation after initial extubation after surgery; or 
patient could not be extubated as planned after surgery. 
Additional secondary outcomes included pulmonary 
embolism, intensive care unit admission, reoperation, 
7-day mortality, and length of hospital stay.
Figure 1: 30-day mortality rates by timing of surgery and development of pulmonary complications
Patients with missing data are included in denominators (appendix p 21). Pulmonary complications are pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. 
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
290 (53·5%) had 
pulmonary 
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Mortality rate 
43·1% (125 deaths)
253 (45·8%) no 
pulmonary 
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Mortality rate 
10·7% (27 deaths)
552 (66·1%) had postoperative 
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Mortality rate 27·9% (154 deaths)
9 patients with 
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835 (74·0%) had emergency surgery
Mortality rate 25·6% (214 deaths)
13 patients with missing data
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Mortality rate 23·8% (268 deaths)
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Mortality rate 18·9% (53 deaths)
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pulmonary 
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Mortality rate 
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SARS-CoV-2 diagnosis
Mortality rate 9·1% (2 deaths)
 
Figure 2: 30-day mortality rates by patient subgroup
Grade of surgery was classified based on the Bupa schedule as either minor 
(minor or intermediate in Bupa schedule) or major (major or complex major in 
Bupa schedule).
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Elective major
Emergency major
Age ≥70 years
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Age <70 years
50 40 30 20 10 0 10 20 30 40 50
30-day mortality rate (%)
Men
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For the Bupa schedule of 
procedures see https://codes.
bupa.co.uk/procedures
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Statistical analysis
The study was done according to STROBE guidelines 
for observational studies.17 Continuous data were tested 
for distribution, with normally distributed data pre-
sented as mean and 95% CI, and differences between 
groups were tested using the unpaired t test. The χ² and 
Fisher’s exact tests were used for categorical data. 
Missing data were included in flowcharts and descriptive 
analyses, allowing denominators to remain consistent 
in calculations.
Multilevel logistic regression was used to calculate odds 
ratios (ORs) and 95% CIs. Models included factors that 
occurred before the outcome of interest. Country was 
included as a random effect with hospital nested within 
country, in both the unadjusted and adjusted models. The 
primary adjusted model included preoperative variables to 
identify predictors of 30-day mortality. Secondary models 
identified predictors of 7-day mortality and pulmonary 
complications. Sensitivity analyses were done, including 
only patients with laboratory-confirmed SARS-CoV-2 
infection; and only patients with preoperatively confirmed 
SARS-CoV-2 infection. Analyses were done using Stata, 
version 15.1 for Mac.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author and analysis group 
had full access to all the data in the study and the corre-
sponding author and the writing committee had final 
responsibility for the decision to submit for publication.
Results
At the time of analysis (May 2, 2020), 30-day follow-up had 
been reached for 1128 patients who had surgery between 
Jan 1 and March 31, 2020. 605 (53·6%) of 1128 patients 
were men and 523 (46·4%) were women, 214 (19·0%) 
were younger than 50 years, 353 (31·3%) were aged 
50–69 years, and 558 (49·5%) were aged 70 years or older, 
with age missing for three patients (table 1).
SARS-CoV-2 infection was diagnosed preoperatively 
in 294 (26·1%) of 1128 patients and postoperatively in 
Figure 3: Adjusted model of predictors for 30-day mortality
1037 patients with complete data were included in the adjusted model. Of the patients excluded because of missing data, seven had died and 84 patients had not 
died at 30 days. ASA=American Society of Anesthesiologists. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. *Adjusted odds ratio reported per unit 
increase in white blood cell count (×10⁹).
Age
<70 years
≥70 years
Sex
Female
Male
ASA grade
1–2
3–5
Unknown
Comorbidities
None
One
Two or more
White blood cell count
Surgical diagnosis
Benign or obstetric
Cancer
Trauma
Urgency
Elective
Emergency
Grade of surgery
Minor
Major
SARS-CoV-2 diagnosis
Preoperative
Postoperative
1
2·30 (1·65–3·22)
1
1·75 (1·28–2·40)
1
2·36 (1·58–3·53)
2·42 (0·86–6·82)
1
1·72 (0·75–3·97)
2·12 (0·95–4·71)
1·00 (0·98–1·03)*
1
1·55 (1·01–2·39)
0·97 (0·65–1·45)
1
1·67 (1·06–2·63)
1
1·52 (1·01–2·31)
1
0·94 (0·65–1·36)
Odds ratio (95% CI)
<0·0001
<0·0001
<0·0001
0·094
0·201
0·066
0·811
0·046
0·890
0·026
0·047
0·753
p value
76/512 (14·8%)
185/525 (25·2%)
92/477 (19·3%)
169/560 (30·2%)
43/356 (12·1%)
212/659 (32·2%)
6/22 (27·3%)
8/108 (7·4%)
39/216 (18·1%)
214/713 (30·0%)
        ··
129/584 (22·1%)
66/239 (27·6%)
66/214 (30·8%)
51/251 (20·3%)
210/786 (26·7%)
40/233 (17·2%)
221/804 (27·5%)
61/279 (21·9%)
200/758 (26·4%)
Mortality rate, n/N (%)
Odds ratio (log10)
–1 0 1 2
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806 (71·5%), with timing of diagnosis missing for 
28 patients. SARS-CoV-2 diagnosis was confirmed by 
laboratory testing in 969 (85·9%) patients, radiological 
findings in 80 (7·1%), and clinical findings in 68 (6·0%), 
with method of diagnosis missing for 11 patients. Overall, 
357 (31·6%) had preoperative thorax CT and the most 
common radiological finding was ground glass opacity 
(table 2).
Emergency surgery was done in 835 (74·0%) of 
1128 patients and elective surgery in 280 (24·8%; table 3), 
with urgency missing for 13 patients. Indications for 
surgery were benign disease in 615 (54·5%), cancer in 
278 (24·6%), and trauma in 227 (20·1%), with indication 
missing for eight patients. 251 (22·3%) procedures were 
categorised as minor and 841 (74·6%) as major, with grade 
of surgery missing for 36 patients. Procedures included 
gastrointestinal and general (373 [33·1%]), orthopaedic 
(302 [26·8%]), cardiothoracic (86 [7·6%]), hepatobiliary 
(62 [5·5%]), obstetric (51 [4·5%]), vascular (45 [4·0%]), 
head and neck (40 [3·5%]), neurosurgery (39 [3·5%]), 
urological (37 [3·3%]), and other (58 [5·1%]) surgeries. 
Procedure type was missing for 36 patients. A full 
breakdown of procedures is in the appendix (pp 11–14).
30-day mortality was 23·8% (268 of 1128). Men had 
higher 30-day mortality than women (28·4% [172 of 605] 
vs 18·2% [94 of 517], p<0·0001). Patients aged 70 years or 
Urgency Grade of surgery
Elective (n=280) Emergency (n=835) p value Minor (n=251) Major (n=841) p value
Mortality
7-day 7 (2·5%) 52 (6·2%) 0·015 8 (3·2%) 51 (6·1%) 0·074
30-day 53 (18·9%) 214 (25·6%) 0·020 41 (16·3%) 226 (26·9%) 0·00055
Missing 2 (0·7%) 11 (1·3%) ·· 1 (0·4%) 8 (1·0%) ··
Pulmonary complications
Composite of pulmonary complications 147 (52·5%) 428 (51·3%) 0·873 116 (46·2%) 455 (54·1%) 0·022
Pneumonia 118 (42·1%) 334 (40·0%) 0·527 94 (37·5%) 355 (42·2%) 0·178
Acute respiratory distress syndrome 41 (14·6%) 119 (14·3%) 0·872 33 (13·2%) 127 (15·1%) 0·442
Unexpected postoperative ventilation ·· ·· 0·262 ·· ·· 0·160
Non-invasive ventilation 23 31 ·· 12 41 ··
Invasive ventilation 40 156 ·· 41 153 ··
Missing 3 21 ·· 4 14 ··
Duration of invasive ventilation ·· ·· 0·049 ·· ·· 0·023
1–23 h 16 32 ·· 7 41 ··
24–47 h 5 27 ·· 3 28 ··
48–71 h 2 21 ·· 3 20 ··
≥72 h 17 79 ·· 29 66 ··
Missing 240 676 ·· 209 686 ··
Pulmonary embolism
30-day 4 (1·4%) 18 (2·2%) 0·449 8 (3·2%) 14 (1·7%) 0·132
Missing 3 21 ·· 4 14 ··
Postoperative intensive care unit 
admission
·· ·· 0·0034 ·· ·· 0·177
None 158 (56·4%) 570 (68·3%) ·· 177 (70·5%) 538 (64·0%) ··
Planned 64 (22·9%) 189 (22·6%) ·· 46 (18·3%) 203 (24·1%) ··
Unplanned from theatre 16 (5·7%) 25 (3·0%) ·· 10 (4·0%) 31 (3·7%) ··
Unplanned from ward 23 (8·2%) 38 (4·6%) ·· 17 (6·8%) 43 (5·1%) ··
Missing 19 (6·8%) 13 (1·6%) ·· 1 (0·4%) 26 (3·1%) ··
Reoperation ·· ·· 0·0015 ·· ·· 0·487
Reoperated 53 (18·9%) 101 (12·1%) ·· 39 (15·5%) 115 (13·7%) ··
Not reoperated 209 (74·6%) 717 (85·9%) ·· 207 (82·5%) 702 (83·5%) ··
Missing 18 (6·4%) 17 (2·0%) ·· 5 (2·0%) 24 (2·9%) ··
Length of stay
Median (IQR), days 13 (5–28) 16 (7–28) 0·012 10 (3–27) 17 (8–29) <0·0001
>30 days 64 (22·9%) 168 (20·1%) 0·352 52 (20·7%) 176 (20·9%) 0·911
Missing 2 (0·7%) 11 (1·3%) ·· 1 (0·4%) 8 (1·0%) ··
Urgency data missing for 13 patients and grade of surgery data missing for 36 patients. Percentages shown are based on the denominator of patients in the subgroup.
Table 4: Postoperative outcomes
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older had higher mortality than patients younger than 
70 years (33·7% [188 of 558] vs 13·9% [79 of 567], 
p<0·0001). Mortality was higher after emergency surgery 
(25·6% [214 of 835]) than elective surgery (18·9% [53 of 
280]; p=0·023; figure 1). Men had higher mortality rates 
than women, and men and women aged 70 years or older 
Figure 4: 30-day mortality rates associated with components of pulmonary complications
Relationships between the pulmonary complications are in the appendix (p 20). *Mortality data were missing for 15 patients; pulmonary complications data were 
also missing for 14 of these patients; the other one patient had a pulmonary complication (unexpected ventilation). 
577 (51·2%) had pulmonary 
complications
Mortality rate 38·0% (219 deaths)*
25 (2·2%) pulmonary complications 
data missing
Mortality rate 12·0% (3 deaths)*
526 (46·6%) no pulmonary 
complications
Mortality rate 8·7% (46 deaths)
1128 patients included
Mortality rate 23·8% (268 deaths)*
456 (40·4%) pneumonia
Mortality rate 37·9% (173 deaths)
240 (21·3%) unexpected ventilation
Mortality rate 41·7% (100 deaths)
162 (14·4%) acute respiratory 
distress syndrome
Mortality rate 63·0% (102 deaths)
Figure 5: Adjusted model of predictors for pulmonary complications
1029 patients with complete data are included in the adjusted model. Of the patients excluded because of missing data, 19 developed pulmonary complications and 
80 patients did not. ASA=American Society of Anesthesiologists. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. *Adjusted odds ratio reported per 
unit increase in white blood cell count (×10⁹).
Age
<70 years
≥70 years
Sex
Female
Male
ASA grade
1–2
3–5
Unknown
Comorbidities
None
One
Two or more
White blood cell count
Surgical diagnosis
Benign or obstetric
Cancer
Trauma
Urgency
Elective
Emergency
Grade of surgery
Minor
Major
SARS-CoV-2 diagnosis
Preoperative
Postoperative
Odds ratio (95% CI) p valuePulmonary complications 
rate, n/N (%)
Odds ratio (log10)
–1 0 1 2
262/509 (51·5%)
296/520 (56·9%)
229/475 (48·2%)
329/554 (59·4%)
146/355 (41·1%)
398/653 (61·0%)
14/21 (66·7%)
42/108 (38·9%)
108/212 (50·9%)
408/709 (57·6%)
         ··
316/579 (54·6%)
134/238 (56·3%)
108/212 (50·9%)
138/250 (55·2%)
420/779 (53·9%)
111/231 (48·1%)
447/798 (56·0%)
140/276 (50·7%)
418/753 (55·5%)
1
1·09 (0·78–1·52)
1
1·45 (1·07–1·96)
1
2·74 (1·89–3·99)
3·73 (1·25–11·19)
1
1·75 (0·97–3·16)
1·62 (0·91–2·87)
1·01 (0·99–1·03)*
1
1·13 (0·72–1·76)
0·95 (0·58–1·43)
1
1·16 (0·75–1·82)
1
1·22 (0·83–1·78)
1
1·41 (0·97–2·05)
0·627
0·016
<0·0001
0·019
0·065
0·101
0·445
0·596
0·698
0·504
0·318
0·076
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had higher rates than those younger than 70 years 
(figure 2).
In adjusted analyses (figure 3; appendix p 15), predictors 
of 30-day mortality were male sex (OR 1·75 [95% CI 
1·28–2·40], p<0·0001), age 70 years or older versus 
younger than 70 years (2·30 [1·65–3·22], p<0·0001), 
ASA grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], 
p<0·0001), malignant versus benign or obstetric diagnosis 
(1·55 [1·01–2·39], p=0·046), emergency versus elective 
surgery (1·67 [1·06–2·63], p=0·026), and major versus 
minor surgery (1·52, [1·01–2·31], p=0·047).
7-day mortality was 5·2% (59 of 1128; table 4). In 
adjusted analyses (appendix p 16), having ASA grades 3–5 
versus grades 1–2 was associated with increased odds of 
7-day mortality (OR 2·52 [95% CI 1·10–5·77], p<0·029), 
whereas post operative diagnosis was associated with 
decreased risk (0·25 [0·13–0·46], p<0·0001).
577 (51·2%) of 1128 patients had at least one pulmonary 
complication (figure 4): 456 (40·4%) had pneumonia, 
240 (21·3%) had unexpected ventilation, and 162 (14·4%) 
had ARDS. Patients who developed pulmonary com-
plications had a higher 30-day mortality than those who 
did not (38·0% [219 of 577] versus 8·7% [46 of 526], 
p<0·0001). Pulmonary complications had occurred in 
219 (81·7%) of 268 patients who died. Among patients 
who dev eloped pulmonary complications, 30-day 
mortality was highest in those who developed ARDS 
(102 [63·0%] of 162). Pulmonary compli cations were 
associated with high 30-day mortality rates across elective 
patients with a postoperative SARS-CoV-2 diagnosis 
(39 [28·3%] of 138), emergency patients with a pre-
operative SARS-CoV-2 diagnosis (53 [39·6%] of 134), and 
emergency patients with a postoperative SARS-CoV-2 
diagnosis (125 [43·1%] of 290; figure 1). Pulmonary 
complication rates were similar in patients with labo ra-
tory-con firmed and clinically diag nosed SARS-CoV-2 
infection (493 [50·9%] of 969 vs 32 [47·1%] of 68, 
p=0·543).
In adjusted analyses (figure 5; appendix p 17) pulmonary 
complications were independently associated with ASA 
grades 3–5 versus grades 1–2 (2·74 [95% CI 1·89–3·99], 
p<0·0001).
At 30 days, pulmonary embolism had occurred in 
22 (2·0%) of 1128 patients. The 30-day mortality rate in 
patients with pulmonary embolism was similar to that 
in patients who did not have pulmonary embolism 
(five [22·7%] of 22 vs 263 [23·8%] of 1106, p=0·909).
In a sensitivity analysis including only patients with 
laboratory-confirmed SARS-CoV-2, the overall 30-day 
mortality rate was 23·7% (230 of 969), and pulmonary 
complications occurred in 493 (50·9%) of 969 patients. 
In adjusted analyses (appendix p 18), predictors of 
30-day mortality were consistent with the main analysis: 
male sex, age 70 years or older, ASA grades 3–5, cancer 
surgery, and emergency surgery. The only independent 
predictor for 30-day pulmonary complications was ASA 
grades 3–5.
In a sensitivity analysis including only patients with 
preoperatively diagnosed SARS-CoV-2, the overall 30-day 
mortality rate was 21·1% (62 of 294), and pulmonary 
complications occurred in 142 (48·3%) of 294 patients. In 
adjusted analyses (appendix p 19), predictors of 30-day 
mortality were male sex and ASA grades 3–5. The only 
independent predictor for 30-day pulmonary compli-
cations was ASA grades 3–5.
Discussion
This study identified that postoperative pulmonary 
complications occur in half of patients with perioperative 
SARS-CoV-2 infection and are associated with high 
mortality. This has direct implications for clinical practice 
around the world. The increased risks associated with 
SARS-CoV-2 infection should be balanced against the 
risks of delaying surgery in individual patients; this study 
identified men, people aged 70 years or older, those with 
comorbidities (ASA grades 3–5), those having cancer 
surgery, and those needing emergency or major surgery 
as being most vulnerable to adverse outcomes.
Thresholds for surgery during the SARS-CoV-2 
pandemic should be higher than during normal practice. 
Men aged 70 years and over who have emergency or 
major elective surgery are at particularly high risk of 
mortality, although minor elective surgery is also 
associated with higher-than-usual mortality. During 
SARS-CoV-2 outbreaks, consideration should be given for 
postponing non-critical procedures and promoting non-
operative treatment to delay or avoid the need for surgery.18
Postoperative outcomes in SARS-CoV-2-infected patients 
are substantially worse than pre-pandemic baseline rates 
of pulmonary complications and mortality. The overall 
30-day mortality in this study was 23·8%, and was high 
across all patient subgroups; all-cause mortality rates were 
18·9% in elective patients, 25·6% in emergency patients, 
16·3% in patients who had minor surgery, and 26·9% in 
patients who had major surgery. SARS-CoV-2-infected 
patients had greater mortality than even the highest-risk 
subgroups of the UK’s NELA. The 2019 NELA report 
presented 30-day mortality rates of 16·9% in patients with 
a high preoperative risk of death, 16·8% in patients with 
an unexpected critical care admission, and 23·4% in frail 
patients older than 70 years.19 The mortality rates identified 
in this study are also higher than those previously reported 
across international settings; a study across 58 countries, 
including low-income and middle-income countries, 
reported a 30-day mortality of 14·9% in the high-risk 
subgroup who had emergency midline laparotomy.20 Post-
operative mortality rates in SARS-CoV-2-infected patients 
with postoperative pulmonary complications approach 
those of the sickest patients with community-acquired 
COVID-19 who are admitted to intensive care.21
Mortality in patients with SARS-CoV-2 was mainly in 
those who had postoperative pulmonary complications, 
which was about 50% of patients. This rate is far 
higher than the pre-pandemic baseline; in the POPULAR 
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multicentre, prospective, observational study of 211 hos-
pitals from 28 European countries in 2014–15, the 
pulmonary complication rate was 8%.5 In our study, 
ARDS had the highest mortality rate of the different 
complications (mortality 63·0%) and occurred much 
more frequently (20%) than reported in the pre-pandemic 
African Surgical Outcomes Study (0·05%).22 In another 
study of high-risk ASA grade 3 patients undergoing non-
cardiac surgery in seven US centres, 0·2% developed 
ARDS, with an overall mortality related to postoperative 
pulmonary complications of 2·3%.23 Even considering 
differences in the case-mix, the incidence of and mortality 
associated with pulmonary complications in SARS-CoV-2-
infected patients is disproportionately high.
This study has limitations. Protocols for laboratory 
testing and radiological interpretation were not stan-
dardised across participating centres. We describe 
outcomes in the early phases of the pandemic when 
routine testing was not available across all sites; setting 
study inclusion criteria requiring laboratory-confirmed 
SARS-CoV-2 would have excluded some infected patients. 
Therefore, patients who did not have a laboratory test or 
CT scan were eligible for inclusion on the basis of clinical 
diagnosis. Only a minority of patients (6·0%) were 
included on the basis of a clinical diagnosis and these 
patients had similar clinical outcomes to patients with 
laboratory-confirmed SARS-CoV-2. The limitations of 
laboratory testing mean that some infected patients 
were excluded from the study based on false negative 
laboratory test results. Future studies need to make 
recommendations on the role of preoperative testing in 
patient selection for surgery.
The study included patients having any type of surgery 
and although this has produced generalisable results, it 
is possible that in large hospitals investigators might 
have not identified all patients. To mitigate this, the 
importance of identifying and enrolling all eligible 
patients was highlighted in training packages for local 
site investigators and strategies to support comprehensive 
patient identification were shared regu larly with all sites. 
Final case ascertainment and data completeness were 
confirmed with local principal investigators, creating as 
robust a dataset as possible. As far as we are aware, this is 
the first international study assessing mortality rates 
after surgery in patients with SARS-CoV-2 infection, and 
the first that reaches across all surgical specialties.24–27 It 
was not feasible for all participating hospitals, many of 
which were experiencing significant stress, to collect data 
on all patients who had surgery during the pandemic 
period. Consequently, this study’s findings should be 
interpreted with caution because they have been 
benchmarked against pulmonary complication and 
mortality rates from high-quality pre-pandemic studies, 
rather than against contemporaneous non-SARS-CoV-2-
infected comparators.
Data were collected in hospitals with ongoing SARS-CoV-2 
infection outbreaks, which were predominantly in Europe 
and North America at the time of this study. As the 
pandemic continues, the evidence this study provides will 
be relevant to countries where large-scale outbreaks might 
take place in the future. To facilitate rapid study approvals, 
this study has focused on key outcomes (mortality and 
pulmonary complications) that can be collected using 
routine data. To support decision making by patients and 
surgeons, future studies should collect longer-term and 
patient-centred outcomes.
When hospitals resume routine surgery, it is likely to be 
in environments that remain exposed to SARS-CoV-2. In 
the future, routine preoperative screening for SARS-CoV-2 
might be possible with rapid tests that have low false 
positive rates, but hospital-acquired infection would 
remain a challenge.12,28 Strategies are urgently required to 
minimise in-hospital SARS-CoV-2 transmission and 
mitigate the risk of postoperative pulmonary compli-
cations in SARS-CoV-2-infected patients whose surgery 
cannot be delayed.
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